The short version of 冻干粉 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-25. Anything still debated is marked as such rather than presented as settled.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
A study by Latinobarómetro in 2023 estimates that 50.3% of the population are Mestizo, 26.4% are White, 9.5% are Indigenous, 9.0% are Black, 4.4% are Mulatto, and 0.4% are Asian, these estimates would equate to around 26 million people being Mestizo, 14 million being White, 5 million being Indigenous, 5 million being Black, 2 million being Mulatto, and 200k being Asian.
=== Lycopene === Lycopene is a key intermediate in the biosynthesis of beta-carotene and xanthophylls. Lycopene may be the most powerful carotenoid quencher of singlet oxygen. Due to its strong color and non-toxicity, lycopene is a useful food coloring (registered as E160d) and is approved for usage in the US, Australia and New Zealand (registered as 160d) and the EU.
Robert Fripp – guitar, keyboards, Mellotron, electronics (1968–1974, 1981–1984, 1994–2008, 2013–2021) Mel Collins – saxophones, flute, bass flute, clarinet, bass clarinet, Mellotron, backing vocals (1970–1972, 2013–2021) Tony Levin – bass guitar, Chapman Stick, upright bass, synthesisers, backing vocals (1981–1984, 1994–1999, 2003–2008, 2013–2021) Pat Mastelotto – drums, percussion, programming (1994–2008, 2013–2021) Gavin Harrison – drums, percussion (2007–2008, 2013–2021) Jakko Jakszyk – lead vocals, guitar, flute, keyboards (2013–2021) Jeremy Stacey – drums, keyboards, backing vocals (2016–2021)
Ireland, as of 2016, was the second-biggest per capita consumer of tea in the world, after Turkey. Local blends are the most common in Ireland, including Irish breakfast tea, using Rwandan, Kenyan and Assam teas. The annual national average of tea consumption in Ireland is 2.7 kg to 4 kg per person. Tea in Ireland is usually taken with milk or sugar and brewed longer for a stronger taste. Turkish tea is an important part of that country's cuisine and is the most commonly consumed hot drink, despite the country's long history with coffee. In 2004, Turkey produced 205,500 tonnes of tea (6.4% of the global total), which made it one of the largest tea markets in the world, with 120,000 tons being consumed in Turkey and the rest being exported. In 2010, Turkey had the highest per capita consumption in the world at 2.7 kg. As of 2013, the per-capita consumption of Turkish tea exceeds 10 cups per day and 13.8 kg per year. Tea is grown mostly in Rize Province on the Black Sea coast.
Minnich, V.; Smith, M. B.; Brauner, M. J.; Majerus, P. W. (March 1971). "Glutathione biosynthesis in human erythrocytes. I. Identification of the enzymes of glutathione synthesis in hemolysates". The Journal of Clinical Investigation. 50 (3): 507–513. doi:10.1172/JCI106519. ISSN 0021-9738. PMC 291957. PMID 5545117. Majerus, P. W.; Brauner, M. J.; Smith, M. B.; Minnich, V. (August 1971). "Glutathione synthesis in human erythrocytes. II. Purification and properties of the enzymes of glutathione biosynthesis". The Journal of Clinical Investigation. 50 (8): 1637–1643. doi:10.1172/JCI106652. ISSN 0021-9738. PMC 442063. PMID 5097571.
Sources: en.wikipedia.org
Hofmann rearrangement of 3,4,5-trimethoxyphenylpropionamide. Cyanohydrin reaction between potassium cyanide and 3,4,5-trimethoxybenzaldehyde followed by acetylation and reduction. Henry reaction of 3,4,5-trimethoxybenzaldehyde with nitromethane followed by nitro compound reduction of ω-nitrotrimethoxystyrene. This was the method used by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). Ozonolysis of elemicin followed by reductive amination. Ester reduction of Eudesmic acid's methyl ester followed by halogenation, Kolbe nitrile synthesis, and nitrile reduction. Amide reduction of 3,4,5-trimethoxyphenylacetamide. Reduction of 3,4,5-trimethoxy(2-nitrovinyl)benzene with lithium aluminum hydride. Treatment of tricarbonyl-(η6-1,2,3-trimethoxybenzene) chromium complex with acetonitrile carbanion in THF and iodine, followed by reduction of the nitrile with lithium aluminum hydride.
==== Clostridioides difficile diarrhea ==== The first study on dogs used for the detection of infectious diseases was conducted by Bomers et al. in 2012. The dogs were trained with food rewards to detect individuals with C. difficile diarrhea, and the results showed 100% specificity and sensitivity in the detection in stool samples. They were also capable of surveilling C. difficile in the environment with 92.3% sensitivity and 95.4% specificity for both odor detection and the ability to locate the source. Vancouver Canada hospital's canine scent recognition program also reported observing dogs' promising ability to detect C. difficile on hospital surfaces, equipment, and C. difficile reservoirs. The advantage of using trained dogs to detect C. difficile compared to the traditional culture-based diagnostic method is the fast detection speed, which only takes a few minutes. Whether sniffing dogs could be universally employed for diagnosing C. difficile is dubious as although it yields the results faster than the preexisting nucleic amplification test, its responsiveness is significantly lower.
Baricitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits Janus kinase 1 with a half maximal inhibitory concentration (IC50) of 5.9 nM and Janus kinase 2 with an IC50 of 5.7 nM. Tyrosine kinase 2, which belongs to the same enzyme family, is affected less (IC50 = 53 nM), and Janus kinase 3 far less (IC50 > 400 nM). Via a signal transduction pathway involving STAT proteins, this ultimately modulates gene expression in immunological cells. Other JAK inhibitors include tofacitinib, which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; fedratinib, and ruxolitinib.
26 June – Lecturers at Stirling University belonging to the Universities and Colleges Union announce a three-day strike beginning the following day amid claims their wages have been reduced by 50% for participating in a UK-wide marking boycott. 29 June – Lord Advocate Dorothy Bain launches a legal bid to overturn a 1997 ruling on evidence in rape cases that could allow more cases to be prosecuted.
== Efficiency == The main limitation in the use of MLC is the reduction in efficiency (peak broadening) that is observed when purely aqueous micellar mobile phases are used. Several explanations for the poor efficiency have been theorized. Poor wetting of the stationary phase by the micellar aqueous mobile phase, slow mass transfer between the micelles and the stationary phase, and poor mass transfer within the stationary phase have all been postulated as possible causes. To enhance efficiency, the most common approaches have been the addition of small amounts of isopropyl alcohol and increase in temperature. A review by Berthod studied the combined theories presented above and applied the Knox equation to independently determine the cause of the reduced efficiency. The Knox equation is commonly used in HPLC to describe the different contributions to overall band broadening of a solute. The Knox equation is expressed as:
Sources: en.wikipedia.org
Radiation protection continued to develop with the invention of new measuring devices such as the chromoradiometer by Guido Holzknecht (1872-1931) in 1902, the radiometer by Raymond Sabouraud (1864-1938) and Henri Noiré (1878–1937) in 1904/05, and the quantimeter by Robert Kienböck (1873-1951) in 1905, which made it possible to determine maximum doses at which there was a high probability that no skin changes would occur. Radium was also included by the British Roentgen Society, which published its first memorandum on radium protection in 1921.
== History == While working on her dissertation, Evelyn M. Anderson co-discovered ACTH with James Bertram Collip and David Landsborough Thomson and, in a paper published in 1933, explained its function in the body. An active synthetic form of ACTH, consisting of the first 23 amino acids of native ACTH, was first made by Klaus Hofmann at the University of Pittsburgh.
Addition of antipsychotics, which are potent dopamine receptor antagonists, to SSRIs, has been found to significantly augment their effectiveness in the treatment of OCD. As such, besides strong serotonin reuptake inhibition, clomipramine at high doses might also block dopamine receptors to treat OCD symptoms, and this could additionally or alternatively be involved in its possible effectiveness advantage over SSRIs. For this reason, it may also be that augmentation with neuroleptics (a common procedure in the occurrence of inadequate response to monotherapy with an SRI) is needed with less frequency with clomipramine relative to SSRIs, the latter of-which apparently lack significant activity as dopamine-receptor antagonists. Although clomipramine is probably more effective in the treatment of OCD compared to SSRIs, it is greatly inferior to them in terms of tolerability and safety due to its lack of selectivity for the SERT and promiscuous pharmacological activity. In addition, clomipramine has high toxicity in overdose and can potentially result in death, whereas death rarely, if ever, occurs with overdose of SSRIs. It is for these reasons that clomipramine, in spite of potentially superior effectiveness to SSRIs, is now rarely used as a first-line agent in the treatment of OCD, with SSRIs being used as first-line therapies instead and clomipramine generally being reserved for more severe cases and as a second-line agent.
== Purpose == Pharmacokinetics simulation gives an insight to drug efficacy and safety before exposure of individuals to the new drug that might help to improve the design of a clinical trial. Pharmacokinetics simulations help in addition in therapy planning, to stay within the therapeutic range under various physiological and pathophysiological conditions, e.g., chronic kidney disease.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.